Response.

Denis L Jardim, Maria Schwaederle, J Jack Lee, Caimiao Wei, John Mendelsohn, Richard L Schilsky, Razelle Kurzrock

Abstract readLetterComment

In one paragraph

Article in Journal of the National Cancer Institute, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Denis L JardimDepartment of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

Maria SchwaederleDepartment of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

J Jack LeeDepartment of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

Caimiao WeiDepartment of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

John MendelsohnDepartment of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

Richard L SchilskyDepartment of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

Razelle KurzrockDepartment of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorDrug ApprovalMolecular Targeted TherapyAntineoplastic AgentsHumansAntineoplastic AgentsBiomarkers, Tumor

Identifiers

PMID26912651

DOI10.1093/jnci/djw001

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.